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February 2005374 Letters to the Editorblockers may also act as antioxidants above their antihypertensive
properties.4,5
Many of the risk factors that predispose to atherosclerosis can
also cause endothelial dysfunction, and the presence of multiple
risk factors, such as hypercholesterolemia, arterial hypertension,
smoking, diabetes mellitus, and obesity, has been found to predict
endothelial dysfunction.1 Thus, it is conceivable that the modifi-
cation of these risk factors should be a further therapeutical ap-
proach to reduce oxidative stress. A better understanding of the
complexity of cellular redox reactions and the development of
sensitive and specific biomarkers that can be used clinically to assess
the oxidative stress phenotypes might improve strategies in the
treatment and prevention of atherosclerosis in the future.
Thomas Mueller, MD
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Regarding “Deep venous thrombosis after
radiofrequency ablation of greater saphenous vein”
The recent article by Hingorani et al (J Vasc Surg 2004;40:
500-4) reports a 16% (12/73) incidence of deep vein thrombosis
in patients undergoing radiofrequency ablation of incompetent
great saphenous veins for symptomatic venous insufficiency. This is
a disturbing statistic considering the many individuals who suffer
from this disorder and the potential benefit radiofrequency abla-
tion can offer over ligation and stripping of the great saphenous
vein. Scrutiny of the article did not provide insight into why this
group of patients had such a high complication rate.
At Jobst Vascular Center, we have had a relatively large
experience with this same procedure (approximately 1500 cases)
for similar indications. Our deep vein thrombosis rate is 0.3%.
Some technical points that we incorporate that may differ from the
article are mentioned for consideration:
1. A limited coagulopathy screen (at least an activated protein C
resistance) is ordered preoperatively for any patient with a history
of thrombophlebitis, deep vein thrombosis, or a family history of
deep vein thrombosis.
2. For patients at risk, low-molecular-weight heparin is adminis-
tered postoperatively, and Coumadin also, if necessary.
3. All patients are scanned intraoperatively after radiofrequency
ablation and postoperatively within 5 days if the saphenofemoral
junction was not ligated. Although initially we ligated the saphe-
nofemoral junction 87% of the time, the percentage of cases we
ligate has decreased significantly.
4. A guidewire (0.025 inch) is used only if difficulty is encoun-
tered passing the catheter so as to minimize endothelial injury to
the common femoral vein caused by a foreign body in a un-
anticoagulated patient. Efforts are made to keep the wire and
catheter out of the deep venous system.5. The radiofrequency electrodes are positioned just below the
inferior epigastric vein, and once in place, the leg is not moved
during the first 10 cm of pullback. Flexion of the knee and
abduction of the hip can cause significant advancement of the
electrodes into the deep venous system.
6. Tumescent anesthesia is generously administered (250 to
400 mL) with particular attention to injecting directly over the
electrodes at the inferior epigastric vein level to ensure that the
great saphenous vein is compressed against the catheter near the
saphenofemoral junction.
7. We prefer 6F catheters, even for larger diameter veins, because
with precise, generous tumescence, good vein wall/electrode con-
tact can be achieved.
8. Increasing the catheter temperature to 90°Cmay increase collagen
denaturation and lumen shrinkage and has not been associated with
skin burns or saphenous nerve injuries in our patients.
We appreciate the willingness of Dr Hingorani and colleagues
to share their preliminary results with us. We would hope that they
would consider reporting subsequent results, perhaps as a letter to
the editor, since, as they so aptly mention in their article, “the
procedure has the promise of improving the care of many of our
patients.”
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The protocol at the Jobst Vascular Center includes a limited
coagulopathy screen, an interesting addition that may identify
higher-risk patients. Furthermore, the addition of a ligation at the
saphenofemoral junction in 87% of a segment of the patients also
may add a level of protection from propagation into the common
femoral vein.
Not all of our surgeons use the guidewire, as often the probe
will pass easily up to the proximal saphenous vein in many patients.
We agree with the amount of tumescent that should be used,
as we have had a similar experience with the volume used, and that
the leg should not be moved after the probe has been positioned.
In addition, after the tumescent has been administered, we also
recheck the position of the probe with duplex imaging before
initiating the ablation.
We have also increased the catheter temperature to 90°C but
still continue to encounter the same degree of postoperative deep
venous thrombosis, despite multiple subsequent visits by the proc-
tors to recheck our technique.
Again, we do still believe in the benefits of the technique and
still continue to perform the technique, even in older patients with
CEAP classifications of 4, 5, and 6. When these deep venous
thromboses have been encountered, they resolve with the outpa-
tient administration of subcutaneous low-molecular-weight hepa-
rin. As more centers are using minimally invasive techniques to
ablate the refluxing saphenous vein, we look forward to examining
the published data of other centers.
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